29.07 12:17 | dpa-AFX: *DZ BANK HEBT FV FÜR ABBVIE AUF 204 (188) USD - 'KAUFEN' |
29.07 12:17 | dpa-AFX: *DZ BANK RAISES FV FÜR ABBVIE TO 204 (188) USD - 'BUY' |
26.07 08:46 | dpa-AFX: European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis |
26.07 08:05 | dpa-AFX: *ABBVIE : EC OKS SKYRIZI FOR TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
25.07 22:13 | MÄRKTE USA/Uneinheitlich nach Vortageseinbruch - Ford unter Druck |
25.07 18:15 | MÄRKTE USA/Börsen nach Vortageseinbruch mit Aufschlägen - Ford unter Druck |
25.07 14:00 | dpa-AFX: AbbVie Q2 24 Earnings Conference Call At 9:00 AM ET |
25.07 13:47 | dpa-AFX: ROUNDUP: AbbVie Boosts FY24 Outlook |
25.07 13:42 | dpa-AFX: AbbVie Q2 Profit Decreases, But Beats Estimates |
25.07 13:42 | dpa-AFX: *ABBVIE Q2 ATTRIBUTABLE NET EARNINGS $1.37 BLN VS $2.02 BLN PRIOR YEAR |
25.07 13:41 | dpa-AFX: *ABBVIE RAISES FY ADJ. EPS GUIDANCE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
25.07 13:39 | dpa-AFX: *ABBVIE RAISES 2024 ADJ. EPS GUIDANCE RANGE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
25.07 13:39 | dpa-AFX: *ABBVIE Q2 NET REVENUES OF $14.462 BLN, INCREASE OF 4.3% ON A REPORTED BASIS AND 5.6% ON OPERATIONAL BASIS |
25.07 13:38 | dpa-AFX: *ABBVIE Q2 EPS $0.77 ON A GAAP BASIS, A DECREASE OF 32.5% |
25.07 13:38 | dpa-AFX: *ABBVIE Q2 ADJ. EPS $2.65, DECREASE OF 8.9% |
12.07 14:48 | dpa-AFX: AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis |
12.07 14:33 | dpa-AFX: *ABBVIE SEEKS FDA AND EMA APPROVAL FOR UPADACITINIB IN GIANT CELL ARTERITIS |
10.07 14:45 | dpa-AFX: AbbVie Appoints Thakkar As EVP Of R&D, Chief Scientific Officer |
10.07 14:03 | dpa-AFX: *ABBVIE APPOINTS ROOPAL THAKKAR AS EVP, RESEARCH & DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER |
01.07 14:17 | dpa-AFX: AbbVie's Robert Michael Assumes Role Of CEO |
|